In VivoRare disease has become a real area of focus and growth for drug development. According to Citeline’s Pharma R&D Annual Review 2023 , more than 30% of all drug development is targeted against rar
ScripHalfway through February, seven different sources of funding for health care and life science innovations have announced newly raised pools of cash totaling $2.2bn for a wide array of technologies, in